Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy VolunteersGlobeNewsWire • 08/16/23
Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 08/10/23
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVIDGlobeNewsWire • 08/07/23
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating DisorderGlobeNewsWire • 07/31/23
Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) TestGlobeNewsWire • 07/24/23
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety DisorderGlobeNewsWire • 07/15/23
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric ObesityGlobeNewsWire • 07/10/23
Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National AcademiesGlobeNewsWire • 07/06/23
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine ProductsGlobeNewsWire • 07/03/23
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLCGlobeNewsWire • 06/26/23
Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 06/15/23
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant CongressGlobeNewsWire • 06/07/23
Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology MeetingGlobeNewsWire • 06/05/23
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant CongressGlobeNewsWire • 05/31/23
Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International ConventionGlobeNewsWire • 05/30/23
Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingGlobeNewsWire • 05/25/23
Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative DiseasesGlobeNewsWire • 05/23/23
Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)GlobeNewsWire • 05/22/23
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare ConferenceGlobeNewsWire • 05/18/23
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating DepressionGlobeNewsWire • 05/17/23
